Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848107 | 0.86 | PPARG (0.47) | PPARGRARGRXRA | |
| SCHEMBL2179645 | 0.84 | PPARG (0.49) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL2180994 | 0.84 | PPARG (0.57) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1847231 | 0.81 | PPARG (0.53) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1851201 | 0.81 | PPARG (0.66) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL2180568 | 0.80 | PPARG (0.70) | PPARGRARGRXRAPPARA | |
| SCHEMBL1849198 | 0.80 | PPARG (0.49) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1848046 | 0.80 | PPARG (0.49) | PPARGRARGRXRAPPARAHRH3 | |
| SCHEMBL1845921 | 0.80 | PPARG (0.41) | PPARGRARGRXRAPPARALMNA | |
| SCHEMBL9325005 | 0.79 | PPARG (0.48) | PPARGRARGRXRAPPARAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | claimed |
| EP-1306086-A2 | Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | claimed |
| EP-0695183-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-07 | — | — | EP | claimed |
| WO-1994025026-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-10 | — | — | WO | claimed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | claimed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | claimed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | claimed |
| US-11021751-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210095345-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS INC (US) | 2021-04-01 | — | — | US | disclosed |
| US-10865449-B2 | Method of identifying disease risk factors | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-2789695-B1 | Anti-Alzheimer's disease treatment of subjects identified by detecting the presence of a genetic variant in the TOMM40 gene at rs 10524523 | ZINFANDEL PHARMACEUTICALS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190032137-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180363060-A1 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2018-12-20 | — | — | US | disclosed |
| US-6288095-B1 | ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC | BEECHAM GROUP P.L.C. (GB) | 2001-09-11 | — | — | US | disclosed |
| EP-0842925-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1998-05-20 | — | — | EP | disclosed |
| US-5646169-A | ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS | BEECHAM GROUP P.L.C. (GB) | 1997-07-08 | — | — | US | disclosed |
| US-5521201-A | SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP P.L.C. | 1996-05-28 | — | — | US | disclosed |
| US-5260445-A | Hypoglycemic | BEECHAM GROUP P.L.C. (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | PPARG 16/4885RARG 1031/4885RXRA 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.